APASL Annual Meeting 2025 in Beijing
Future Meetings
APASL STC 2025 Mumbai
Theme: | Improving non-transplant outcomes in patients with advanced liver disease |
---|---|
Date: | February 7-8, 2025 |
City: | Mumbai, India |
President: | Dr. Akash Shukla |
Website: | https://buildconferences.in/events/ |
APASL STC 2025 Istanbul
Theme: | Liver Cirrhosis: Current and New Therapies |
---|---|
Date: | April 24-26, 2025 |
City: | Istanbul, Turkey |
President: | Dr. Vedat Golal |
Website: | https://apaslstc2025turkey.org/en/ |
APASL STC 2025 Qingdao
Theme: | Full process management of liver transplant patients |
---|---|
Date: | May 10-11, 2025 |
City: | Qingdao, China |
President: | Dr. Jinzhen Cai |
Website: | To be announced. |
APASL STC 2025 Tashkent
Theme: | Viral hepatitis elimination by 2030: Progress and challenges |
---|---|
Date: | June 4-5, 2025 |
City: | Tashkent, Uzbekistan |
President: | Dr. Musabaev Erkin |
Website: | To be announced. |
APASL Oncology 2025 Taipei
Theme: | Oncology-Multifaceted approach and treatment for liver cancer |
---|---|
Date: | September 5-7, 2025 |
City: | Taipei, Taiwan |
President: | Dr. Yi-Hsiang Huang |
Website: | To be announced. |
APASL STC 2025 Moscow
Theme: | Alcoholic liver disease |
---|---|
Date: | September 25-26, 2025 |
City: | Moscow, Russia |
President: | Dr. Andrey Kostin |
Website: | To be announced. |
APASL STC 2025 Tokyo
Theme: | New Horizons for Steatotic Liver Disease: Cutting Edge Research and Emerging Therapeutics |
---|---|
Date: | October 2-3, 2025 |
City: | Tokyo, Japan |
President: | Dr. Kenichi Ikejima |
Website: | https://www.apasl-stc2025tokyo.org |
APASL STC 2025 Yangon
Theme: | Current Management of HCC with Local Relevance |
---|---|
Date: | December, 2025 |
City: | Yangon, Myanmar |
President: | Dr. Kyaw Soe Tun |
Website: | To be announced. |
APASL STC 2025 Karachi
Theme: | MAFLD: From Bench to Bedside |
---|---|
Date: | December 6-7, 2025 |
City: | Karachi, Pakistan |
President: | Dr. Amna Subhaan Butt |
Website: | To be announced. |
APASL Guidelines
APASL Guidelines for HCC -”Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update” (Hepatol Int 2017; 11: 317-370)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HBV -"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update" (Hepatol Int 2016; 10:1–98)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HCV -”APASL consensus statements and recommendation for hepatitis C prevention, epidemiology, and laboratory testing” (Hepatol Int 2016 10:681–701)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HCV -”APASL consensus statements and recommendation on treatment of hepatitis C” (Hepatol Int 2016 10:702–726)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Acute-on-chronic Liver Failure -”Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014” (Hepatol Int 2014; 8: 453-471)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Fibrosis -”Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)” (Hepatol Int 2009; 3: 323-333)
*This APASL Guideline can be downloaded by clicking below.
APASL consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis a 2016 update (Hepatol Int 2017 11:1–30)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for IPH -”Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment” (Hepatol Int 2007; 1: 398-413)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Variceal Bleeding -”Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver” (Hepatol Int 2008; 2: 429-439)
*This APASL Guideline can be downloaded by clicking below.